Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
emilimogene sigulactibac
- Development stage
- Phase 1
- Lead developer
- Ilya Pharma
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Cell Therapies, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Gene Therapies, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Topical, Oral
01
Overview
Emilimogene sigulactibac is a genetically engineered live biotherapeutic product based on *Limosilactobacillus reuteri* bacteria, modified to express and deliver the human chemokine CXCL12 (also known as stromal cell-derived factor 1, SDF-1) at the site of administration. It is being developed primarily for topical treatment of skin wounds, including those associated with STING-associated vasculopathy with onset in infancy (SAVI), diabetic foot ulcers, and other difficult-to-heal wounds. The drug acts by enhancing wound healing through local immunomodulation, collagen modulation, protein replacement effects, and antimicrobial activity against wound pathogens. Oral formulations are also under preclinical development for gastrointestinal indications such as colitis. Emilimogene sigulactibac represents a new-in-class gene therapy approach using engineered bacteria to deliver therapeutic proteins directly at disease sites[2][5][6][8].
- Other names
- emilimogene sigulactibac
02
Targets
CXCR7 (CXC chemokine receptor 7)CXCR4 (C-X-C motif chemokine receptor 4)
Beyond the preview
Go deeper on emilimogene sigulactibac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on emilimogene sigulactibac.